Clinical trials: Stage IIIC Melanoma
Malignant Melanoma
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria [irRECIST 1.1]…
- Trial name
- CALM (NCT01227551)
- Testing
- Coxsackievirus A21 (CVA21)
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Viralytics
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing…
- Conditions
- Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT03719131
- Testing
- Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emory University
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of onalespib when given together with dabrafenib and trametinib in treating patients with BRAF-mutant melanoma or solid tumors that have spread to another place in the…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT02097225
- Testing
- Dabrafenib, Laboratory Biomarker Analysis, Onalespib
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Extraocular Extension Melanoma, Metastatic Intraocular Melanoma
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma
- Trial name
- NCT01533948
- Testing
- axitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent)…
- Conditions
- Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02304458
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIB Melanoma
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body.
- Conditions
- Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT02296112
- Testing
- trametinib, laboratory biomarker analysis, pharmacological study
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Melanoma, Recurrent Melanoma
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma.
- Conditions
- Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
- Trial name
- NCT02965716
- Testing
- Pembrolizumab, Talimogene Laherparepvec
- Where
- 20 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma of Unknown Primary, Recurrent Melanoma
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery.
- Conditions
- Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
- Trial name
- NCT01274338
- Testing
- Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
- Where
- 937 sites in United States, Canada
- Volunteers
- 1,673 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma
- Trial name
- NCT03396952
- Testing
- Aspirin, Ipilimumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
Advanced Melanoma, Metastatic Melanoma
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable).
- Conditions
- Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01134614
- Testing
- Ipilimumab, Sargramostim
- Where
- 257 sites in United States
- Volunteers
- 245 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
- Trial name
- NCT03325101
- Testing
- Cryosurgery, Pembrolizumab, Pheresis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Malignant Melanoma
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
This open-label, multicenter. single arm Phase I dose-escalation study with efficacy tail extension will evaluate the maximum tolerated dose/recommended dose, the safety and efficacy of vemurafenib (RO5185426) in pediatric…
- Trial name
- NCT01519323
- Testing
- vemurafenib
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Recurrent Melanoma, Stage IIIA Skin Melanoma
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph…
- Conditions
- Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
- Trial name
- NCT00019682
- Testing
- Aldesleukin, gp100 Antigen, Montanide ISA 51 VG
- Where
- 19 sites in United States
- Volunteers
- 185 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIA Melanoma
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
This phase II trial is studying how well dasatinib works in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT00436605
- Testing
- dasatinib
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
- Trial name
- NCT01708941
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b
- Where
- 276 sites in United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Malignant Melanoma
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
- Conditions
- Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma
- Trial name
- NCT01321437
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, Axitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, Irvine
Recurrent Melanoma, Stage IIIA Melanoma
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
This phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02094872
- Testing
- cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Yale University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
This phase I trial studies how well tacrolimus, nivolumab, and ipilimumab work in treating kidney transplant recipients with cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT03816332
- Testing
- Ipilimumab, Nivolumab, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)